Benchmarking is crucial for healthcare providers to enhance quality and efficiency, notably for complex conditions like sarcomas. Multidisciplinary teams/sarcoma boards (MDT/SBs) are vital in sarcoma management, but differences in their processes can affect patient outcomes and treatment costs, despite adherence to international guidelines. To address this issue, this study aimed to compare two MDT/SBs and establish an interoperable digital platform, Sarconnector®, for real-time-world data assessment and automated analysis. The study included 983 patients, 46.0% of whom female, with a median age of 58 years, and 4.5% of patients presented with metastasis at diagnosis. Differences were observed in the number of first-time presentations, follow-up presentations, primary sarcomas, biopsies and chemotherapy indications between the two MDT/SB. The results highlight the importance of benchmarking and utilizing a harmonized data approach, such as the RWT approach provided by the Sarconnector®, to standardize and evaluate quality and cost metrics. By identifying areas of improvement and making data-driven decisions on the meta-level, healthcare providers can optimize resources and improve patient outcomes. In conclusion, benchmarking with the RWT harmonized data approach provided by the Sarconnector®can help healthcare providers improve the overall effectiveness of the healthcare system and achieve better outcomes for their patients in terms of both outcomes and costs.
基准测试对于医疗保健提供者提升质量和效率至关重要，尤其对于肉瘤这类复杂病症。多学科团队/肉瘤委员会（MDT/SBs）在肉瘤管理中发挥着关键作用，但即使遵循国际指南，其流程差异仍可能影响患者预后和治疗成本。为解决这一问题，本研究旨在比较两个MDT/SBs，并建立一个可互操作的数字化平台Sarconnector®，用于实时真实世界数据评估和自动化分析。研究共纳入983例患者，其中46.0%为女性，中位年龄58岁，4.5%的患者在诊断时已出现转移。两个MDT/SB在首次就诊数量、随访就诊数量、原发性肉瘤、活检及化疗指征方面存在差异。研究结果凸显了基准测试和采用标准化数据方法（如Sarconnector®提供的RWT方法）对质量与成本指标进行标准化评估的重要性。通过识别改进领域并在元层面做出数据驱动决策，医疗保健提供者能够优化资源配置并改善患者预后。总之，采用Sarconnector®提供的RWT标准化数据方法进行基准测试，可帮助医疗保健提供者提升医疗系统的整体效能，在治疗效果和成本控制两方面实现更好的患者预后。
肿瘤(癌症)患者之家